How A Massive Wall Street Trade Inspired My Stock-Picking Breakthrough
Welcome to the first issue of Power Trends … I can’t wait to share new opportunities, tell you how to survive and thrive…
Read now
Here’s Why the Dow Dogs May Be Crowned Best in Breed in 2023
Here are the 10 stocks in the Dow dog pound for 2023.
Read now
The GEHC Spinoff
In August 2022, we shared how General Electric (GE) was spinning off its healthcare unit into its own publicly traded…
Read now
Bitcoin Has Gained 30% in 2023, but the Better Opportunity Lies in This Investable Sector
TradeSmith Daily readers are getting a sneak peek into another sector that I believe will create huge opportunity for savvy investors in 2023
Read now
Special-Situation Central: 3 Potential Takeover Targets for 2023
With this issue of Special-Situation Central, the team compiled a list of three companies that could be acquired over the next year by larger firms. All three companies offer something unique, ranging from one-of-a-kind sports content to a rich library of hit TV shows to potential treatments for a rare disease.
Read now
Tesla Is Getting Schooled by BYD and Mercedes-Benz
BYD and Mercedes-Benz demonstrate why Tesla has no moat and the shares will fall much further.
Read nowTradeSmith 2023 Investing Outlooks
Our team of experts are always in your corner, which is why we wanted to make sure you could easily access their 2023 investing outlooks:…
Read nowChatGPT and Declining Workforce Participation – What to Know
Any time something like ChatGPT – a user-friendly chatbot that was trained to interact with people in a conversational, humanlike way – is released into…
Read now
Ready to Access: Mike Burnick’s Investing Office Hours
Today, I’ll share my answers to your individual and collective questions that I think will benefit members the most.
Read now
Amgen Set the Record for the Biggest Biotech Acquisition Offer in 2022. Here’s What Our Tools Say about the Stock.
At this price, there isn’t an attractive arbitrage opportunity to take advantage of if Amgen is going to pay $116.50 per share. But what we can look into is what this deal means for Amgen and what our tools say about the stock before the ink on this deal fully dries.
Read now